COVID-19 Impact on Remdesivir in Healthcare Industry

Posted by swarajya on April 7th, 2021

COVID-19 Impact on Remdesivir in Healthcare Industry

OVERVIEW

In early 2020, a new virus has begun to make headlines around the world due to its unprecedented speed of transmission. Its origins can be traced back to the food market in Wuhan, China in December 2019. From there, it has reached countries as far away as the United States and the Philippines. The virus (formally called SARS-CoV-2) is responsible for millions of infections worldwide and causes hundreds and thousands of deaths. The United States is the most affected country. The disease caused by infection with SARS-CoV-2 is called COVID-19, which stands for coronavirus disease 2019. As definitive treatments for confirmed COVID-19 have not yet been identified, there is significant interest in repeating existing antiviral drugs for use against COVID-19.

Several therapies have been evaluated for the treatment of COVID-19, but they have not yet been shown to be effective. Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase inhibitor with inhibitory activity against SARS-CoV and respiratory syndrome in the Middle East (MERS-CoV), was early identified as a promising therapist for COVID-19 due to its ability to inhibit CoV- SARS 2 in vitro. In addition, in studies with non-human primates, remdesivir started, starting 12 hours after MERS-CoV inoculation, lung virus levels and lung damage.

IMPACT ON PRICE 

A large number of challenges are being faced by the various market players due to the coming of the novel coronavirus, one such issue is the uncertainty surrounding the impact of COVID-19 on remdesivir demands. Due to the increased demand of remdesivir for coronavirus treatment and stiff competition between the market players, the price of remdesivir has decreased. Read more…